Fulcrum Therapeutics (FULC) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to -$0.31.
- Fulcrum Therapeutics' EPS (Weighted Average and Diluted) rose 1142.86% to -$0.31 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.21, marking a year-over-year decrease of 29032.26%. This contributed to the annual value of -$156.9 for FY2024, which is 976763.07% down from last year.
- Latest data reveals that Fulcrum Therapeutics reported EPS (Weighted Average and Diluted) of -$0.31 as of Q3 2025, which was up 1142.86% from -$0.28 recorded in Q2 2025.
- Fulcrum Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.87 during Q2 2024, with a 5-year trough of -$267.29 in Q4 2024.
- For the 5-year period, Fulcrum Therapeutics' EPS (Weighted Average and Diluted) averaged around -$16.09, with its median value being -$0.43 (2024).
- Over the last 5 years, Fulcrum Therapeutics' EPS (Weighted Average and Diluted) had its largest YoY gain of 32894.74% in 2024, and its largest YoY loss of 6672369.64% in 2024.
- Fulcrum Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.58 in 2021, then grew by 18.97% to -$0.47 in 2022, then grew by 14.89% to -$0.4 in 2023, then plummeted by 66723.7% to -$267.29 in 2024, then surged by 99.88% to -$0.31 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.31 in Q3 2025, compared to -$0.28 in Q2 2025 and -$267.29 in Q4 2024.